In The News

Pazdur prepared to unveil one pilot program, and previews another: A new pilot project: Project Pragmatica. Several weeks ago, AgencyIQ had confirmed with industry and

Targeted cancer drugs typically require specific tests to identify patients who could benefit the most from the therapies. But as FDA oncology chief Richard Pazdur,

Welcome to another installment of This Week at FDA, your weekly source for updates – big and small – on FDA, drug and medical device

The National Cancer Institute could handle US enrollment of studies testing cancer drugs under a proposal floated by FDA’s cancer chief as part of a

Drug companies need to “step up and take their drugs off the market as rapidly as possible” if a follow-up study shows their fast-tracked product

The FDA’s oncology department, under the leadership of Richard Pazdur, M.D., is getting tougher on accelerated approvals for cancer drugs. When considering accelerated approvals for

FDA Commissioner Rob Califf sat down for a conversation on Thursday morning with Rick Pazdur, head of the FDA’s Oncology Center of Excellence, with the

NEW YORK – Hoping to keep up with an increasing number of clinical assays for DNA repair deficiency, nonprofit Friends of Cancer Research is midway

Many contemporary clinical trials for metastatic renal cell carcinoma incorporate restrictive eligibility criteria, according to study results. “For instance, HIV positivity, as well as hepatitis